Petros Pharmaceuticals Stock Net Income
| PTPI Stock | USD 0.01 0 14.29% |
As of the 10th of February, Petros Pharmaceuticals holds the Variance of 102.29, coefficient of variation of (929.74), and Risk Adjusted Performance of (0.08). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Petros Pharmaceuticals, as well as the relationship between them.
Petros Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Petros Pharmaceuticals' valuation are provided below:Petros Pharmaceuticals does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Petros |
Petros Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Petros Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Petros Pharmaceuticals.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Petros Pharmaceuticals on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Petros Pharmaceuticals or generate 0.0% return on investment in Petros Pharmaceuticals over 90 days. Petros Pharmaceuticals is related to or competes with Shineco, INVO Fertility, Lixte Biotechnology, Celularity, Longevity Health, Concord Medical, and PetVivo Holdings. Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on mens health therapeutics More
Petros Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Petros Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Petros Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 55.0 | |||
| Value At Risk | (14.29) | |||
| Potential Upside | 14.29 |
Petros Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Petros Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Petros Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Petros Pharmaceuticals historical prices to predict the future Petros Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (1.09) | |||
| Total Risk Alpha | (2.21) | |||
| Treynor Ratio | 27.65 |
Petros Pharmaceuticals February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | 27.66 | |||
| Mean Deviation | 6.58 | |||
| Coefficient Of Variation | (929.74) | |||
| Standard Deviation | 10.11 | |||
| Variance | 102.29 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (1.09) | |||
| Total Risk Alpha | (2.21) | |||
| Treynor Ratio | 27.65 | |||
| Maximum Drawdown | 55.0 | |||
| Value At Risk | (14.29) | |||
| Potential Upside | 14.29 | |||
| Skewness | 0.6401 | |||
| Kurtosis | 2.74 |
Petros Pharmaceuticals Backtested Returns
Petros Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of -0.0825, which implies the firm had a -0.0825 % return per unit of risk over the last 3 months. Petros Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Petros Pharmaceuticals' Variance of 102.29, coefficient of variation of (929.74), and Risk Adjusted Performance of (0.08) to confirm the risk estimate we provide. The company holds a Beta of -0.0397, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Petros Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Petros Pharmaceuticals is likely to outperform the market. At this point, Petros Pharmaceuticals has a negative expected return of -0.84%. Please make sure to check Petros Pharmaceuticals' value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Petros Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.13 |
Insignificant reverse predictability
Petros Pharmaceuticals has insignificant reverse predictability. Overlapping area represents the amount of predictability between Petros Pharmaceuticals time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Petros Pharmaceuticals price movement. The serial correlation of -0.13 indicates that less than 13.0% of current Petros Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.13 | |
| Spearman Rank Test | -0.26 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Petros Pharmaceuticals reported net income of (14.32 Million). This is 104.2% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 102.51% higher than that of the company.
Petros Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Petros Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Petros Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Petros Pharmaceuticals by comparing valuation metrics of similar companies.Petros Pharmaceuticals is currently under evaluation in net income category among its peers.
Petros Fundamentals
| Return On Equity | -5.71 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (2.80) % | |||
| Operating Margin | (2.41) % | |||
| Current Valuation | (1.42 M) | |||
| Shares Outstanding | 2.14 M | |||
| Shares Owned By Insiders | 7.39 % | |||
| Shares Owned By Institutions | 6.79 % | |||
| Number Of Shares Shorted | 12.35 M | |||
| Price To Book | 0.45 X | |||
| Price To Sales | 0.05 X | |||
| Revenue | 5.11 M | |||
| Gross Profit | 3.9 M | |||
| EBITDA | (10.81 M) | |||
| Net Income | (14.32 M) | |||
| Cash And Equivalents | 13.3 M | |||
| Cash Per Share | 0.64 X | |||
| Total Debt | 7.39 M | |||
| Debt To Equity | 0.31 % | |||
| Current Ratio | 3.10 X | |||
| Book Value Per Share | (17.73) X | |||
| Cash Flow From Operations | (2.6 M) | |||
| Short Ratio | 0.17 X | |||
| Earnings Per Share | (63.15) X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 18 | |||
| Beta | 2.2 | |||
| Market Capitalization | 265.45 K | |||
| Total Asset | 10.64 M | |||
| Retained Earnings | (113.21 M) | |||
| Working Capital | (10.73 M) | |||
| Net Asset | 10.64 M |
About Petros Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Petros Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Petros Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Petros Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Petros Pink Sheet
Petros Pharmaceuticals financial ratios help investors to determine whether Petros Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Petros with respect to the benefits of owning Petros Pharmaceuticals security.